The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1762
August 31, 2026
View Complete Issue         Table of Contents 2019 
Enlicitide (Lipfendra) – An Oral PCSK9 Inhibitor for LDL-Cholesterol Lowering
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Enlicitide (Lipfendra) – An Oral PCSK9 Inhibitor for LDL-Cholesterol Lowering
August 31, 2026 (Issue: 1762)
Enlicitide (Lipfendra – Merck), an oral proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, has been approved by the FDA to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Enlicitide (Lipfendra) – An Oral PCSK9 Inhibitor for LDL-Cholesterol Lowering
Article code: 1762a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.